Comparison of Different Invasive Devices for the Treatment of Urinary Incontinence after Radical Prostatectomy

Table 2

36 prospective clinical trials included in the analysis: main characteristics of the population. Number of cases; mean ± SD or median and (range).

Author	No. of patients	Treatment groups (A, B, C, D, and E)	Mean age (years)	BMI	Follow-up (months)	Adjuvant RT (% pz)	Measurements
Suzuki et al. [10]	4	B	70.6 (64–76)	—	6	ND	n pad/die, urodynamic
Suzuki et al. [10]	4	B	70.6 (64–76)	—	6	ND	n pad/die, urodynamic
Migliari et al. [11]	49	B	70.5 (65–75)	—	32	ND	n pad/die, urodynamic
Bauer et al. [31]	115	B	69.0 (47–82)	—	36	ND	24 h Pad test; ICIQ-UI; urodynamic
Bauer et al. [30]	137	B	69.5 (56–82)	—	27	13.5	1 h Pad test; n pad/die; urodynamic;
Migliari et al. [37]	9	B	74.0 (66–80)	—	6	ND	% Pad free, urodynamic
Bauer et al. [12]	124	B	68.9 (54–87)	—	6	13.0	n pad/1-hour pad test. 24-hour pad test
Ferro et al. [28]	29	B	65.5 ± 4.7	24.7	36	0	n pad, 24 h pad test, ICQ-SF, urodynamic
Galiano et al. [27]	52	B	64.9 ± 5.1	27.6 ± 3.6	12	8.8	n pad/die
Leruth et al. [23]	173	B	67.7 ± 7.3 (46–83)	26.6 ± 4.9	60	12.1	% Pad free, urodynamic
Zaragoza et al. [22]	4	B	65.0 (58–72)	—	12	ND	n pad/die
John et al. [21]	16	B	67.0 (56–83)	—	14	ND	n pad/die, urodynamic
Collado et al. [15]	94	B	66.0 (52–80)	27.5 (21–39)	49	ND	n pad/die 24 h pad test
Collado et al. [14]	27	B	66.0 (48–72)	—	18	ND	n pad/die, ICIQ-UI-SF, urodynamics
Trigo Rocha et al. [36]	40	D	68.3 ± 6.3	—	53.4	0	VAS score; n pad/die; urodynamic
Correia Lima et al. [32]	15	D	68.2 ± 7.5	26.61 ± 4.1	19.7	ND	Pad weight test, ICIQ - SF,
Lai et al. [24]	129	D	69.0 ± 0.6	—	34.1	26.0	n pad/die, urodynamic
Trigo Rocha et al. [20]	25	E	68.6	—	22.4	ND	n pad/die, urodynamic
Bauer et al. [41]	24	B	71.0 (61–77)	—	18	100	n pad/die, 1 h pad weigh, ICIQ-UI-SF
Noordhof et al. [35]	143	E	69.0 (66–73)	26,1 (24.1–28.1)	46	ND	n pad/die
Seweryn et al. [34]	38	C	70.0 (60–83)	—	17	44.7	n pad/die, urodynamic
Kim et al. [33]	64	C	69.58 ± 7.52	—	46	12.0	n pad/die
Renè Yiou et al. [25]	20	E	68.6 ± 9.0	—	12	ND	n pad, ICIQ-SF
Renè Yiou et al. [29]	40	B	67.7 ± 7.0	—	24	5.0	UCLA-PCI; ICIQ-SF;; n pad/die
Hoda et al. [26]	124	C	71.2 ± 5.5	—	19.1	35.0	n pad, urodynamic
Hoda et al. [26]	99	C	70.4 (55–86)	—	30	31.0	24 h Pad test, n pad/die, urodynamic
Martens et al. [19]	29	E	65.0 (61–75)	—	41	ND	n pad/die
Introini et al. [18]	66	C	66.0 (52–79)	—	26	7.5	% Pad free
Le Portz et al. [17]	93	B	72.5 ± 6.5	26.2	24	ND	n pad/die, 24 h pad test, urodynamic
Dikranian et al. [16]	20	A	64.8 (56–78)	—	6	5.5	Questionnaire, n pad/die, urodynamic
Dikranian et al. [16]	16	B	62.8 (63–72)	—	6	2.7	Questionnaire, n pad/die, urodynamic
Gregori et al. [13]	11	E	69.9 (64–77)	—	8	9.1	24 h Pad test
Cestari et al. [9]	120	B	64.0 (51–79)	25.6 (21.1–31.2)	12	0	n pad/die, ICIQ-UI-SF
Van Uhm et al. [38]	10	A	67.0 ± 6.1	29.7 ± 6.3	6	0	24 h Pad weight, ICIQ-SF, urodynamics
Cestari et al. [39]	60	B	65.0 (60–72)	25.3	12	ND	n pad/die, ICIQ-UI-SF
Stephen J et al. [40]	15	B	60.2 (49–71)	—	12	ND	n pad/die
Crivellaro et al. [21]	46	E	67.0 (45–82)	—	19	ND	n pad/die, UCLA, urodynamic
Crivellaro et al. [21]	38	B	65.0 (30–81)	—	33	ND	n Pad/die, UCL, urodynamic
Queissert et al. [43]	12	C	69.0 (64–72)	26.4	12	ND	Pad weight, n pad/die, Urodynamic, ICIQ-UI-SF

Note. ND = not defined. Treatment group: A = bulking agent, B = fixed sling, C = adjustable sling, D = artificial sphincter, and E = ProACT. Grey horizontal rows represent the second arm of treatment in the same trial.